ARDT
Ardent Health Partners, LLC
ARDT's fundamentals are mixed, but it looks expensive: trading at 17x earnings, about twice its usual 9.0x. Analysts expect strong earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARDT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
ARDT's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARDT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.5x | $6.75 | -62% |
| Fair | 9x | $9.25 | -48% |
| Forward | 15x | $17.68 | — |
| Current | 17x | $17.68 | — |
| Expensive | 20x | $20.97 | +19% |
Historical ranges are pointers, not guarantees.
ARDT's PE is in its expensive range at 17x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARDT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect ARDT's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARDT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.21 | +17% |
| Q3 2026 | $1.03 | -30% |
| Q2 2026 | $0.55 | -70% |
| Q1 2026 | $0.95 | -42% |
| Q4 2025 | $0.96 | -38% |
| Q3 2025 | $1.47 | +119% |
| Q2 2025 | $1.83 | +190% |
| Q1 2025 | $1.65 | +217% |
| Q4 2024 | $1.55 | +343% |
ARDT has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ARDT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.6B | +3.1% |
| Q2 2026 | $1.6B | -1.4% |
| Q1 2026 | $1.6B | +7% |
| Q4 2025 | $1.6B | -0.1% |
| Q3 2025 | $1.6B | +8.8% |
| Q2 2025 | $1.6B | +12% |
| Q1 2025 | $1.5B | +4% |
| Q4 2024 | $1.6B | +19% |
ARDT's revenue grew through 2024 and has held roughly level since: $1.6B last quarter, up 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5% | +5.1 points |
| Q2 2026 | 2.7% | -4.8 points |
| Q1 2026 | 4.7% | -0.3 points |
| Q4 2025 | 5.8% | -4.7 points |
| Q3 2025 | -0.1% | -4.1 points |
| Q2 2025 | 7.4% | +1.8 points |
| Q1 2025 | 5% | -0.3 points |
| Q4 2024 | 10% | -2.4 points |
ARDT has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ARDT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ARDT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121.9M | -21% |
| Q2 2026 | $196.7M | +67% |
| Q1 2026 | -$60.2M | -$35.4M |
| Q4 2025 | $223.4M | +87% |
| Q3 2025 | $154.4M | +72% |
| Q1 2025 | -$24.8M | +$13.7M |
| Q4 2024 | $119.6M | +1090% |
| Q3 2024 | $89.7M | +41% |
ARDT generated $482M in free cash flow over the past year, up 31% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ARDT on cash flow, with more consistent year-over-year improvement.
ARDT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.9% | -1.3M shares |
| 1 year | +0.3% | +478K shares |
| 3 years | +0.5% | +741K shares |
| 5 years | +86% | +65.7M shares |
ARDT has 142M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $11M |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2018 | — |
| Q3 2018 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ARDT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARDT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 1.0x | Healthy |
| Q1 2026 | 1.1x | Healthy |
| Q4 2025 | 0.9x | Very low |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.0x | Healthy |
| Q1 2024 | 5.1x | High |
| Q4 2023 | 5.5x | High |
ARDT's net debt is less than a year of its operating earnings (EBITDA).
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ARDT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 82.1 | Overbought |
| Stochastic | 88.7 | Overbought |
ARDT's weekly RSI is 82 (overbought) and its Stochastic is 89 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARDT PE vs Healthcare Sector
| Metric | ARDT | Sector median | Relative |
|---|---|---|---|
| PE | 17x | 26x | 34% below |
| PE % | 75 | 54 | 21 pts above |
ARDT is trading at 17x earnings, a 34% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARDT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.9 | 37% above |
| 20 week MA | $11.6 | 52% above |
| 50 week MA | $10.1 | 74% above |
| 100 week MA | $11.8 | 50% above |
ARDT has stronger trend alignment. ARDT is above 4 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARDT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.3 | $16.9 | -2.3% |
| 2025 | $16.9 | $9.22 | -45% |
| 2026 YTD | $9.22 | $17.7 | +92% |
ARDT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.